Introduction
It is well established that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of type 2 diabetes, the metabolic syndrome, cardiovascular disease, and advanced liver disease (1) .
Hepatic fat accumulation is tightly linked to hepatic insulin resistance, and characterized by decreased ability of insulin to suppress hepatic glucose and triglyceride-rich VLDL particle production in the liver (1) . This in turn leads to hyperglycemia, hypertriglyceridemia, and a low HDL cholesterol concentration. Hepatic insulin resistance is thus likely to be a core component of the metabolic syndrome (2).
When estimated using 1 H-MRS, every third adult has a fatty liver (3) . There is a need to identify novel specific markers of hepatic fat, because 1 H-MRS is not available in clinical practice, and current markers of hepatic steatosis, such as S-ALT, S-AST, fS-insulin, and fS-C-peptide, are both insensitive and unspecific (4) . Assessment of hepatic insulin sensitivity by state-of-the-art methodology requires prolonged insulin and glucose infusions in combination with glucose tracer.
Because these measurements are complicated and costly, they also cannot be used in routine clinical practice. FS-insulin concentrations are often used as a marker of hepatic insulin sensitivity, but they are influenced by insulin resistance in tissues other than the liver, as well as by insulin clearance, and insulin secretion.
IGFBP-1 belongs to a 6-member family of IGFBP:s, which modulate the bioavailability of IGF-1 (5) . We have previously shown that insulin decreases IGFBP-1 concentrations acutely in vivo (6) , and the liver has been shown to be the main site of production of insulin-like growth factor binding protein-1 (IGFBP-1) in humans (7) . Previous studies have shown that serum IGFBP-1 concentrations are negatively related to indirect estimates of insulin resistance, such as HOMA-IR (8) (9) (10) , and positively to whole-body insulin sensitivity measured using the euglycemic hyperinsulinemic clamp technique (11) (12) (13) . The associations between serum IGFBP-1 concentrations, liver fat, and directly measured hepatic insulin sensitivity have not previously been examined.
In the present study, we measured liver fat using 1 H-MRS, serum IGFBP-1 concentrations, and other features of insulin resistance in 113 non-diabetic subjects. Hepatic insulin sensitivity was measured directly by use of a prolonged low dose (0.3 mU/kg min) insulin infusion in combination with [3-
Methods

Subjects and study design
A total of 113 non-diabetic subjects were recruited using the following inclusion criteria: (i) age 18 to 60 years; (ii) no known acute or chronic disease based on history, physical examination and standard laboratory tests (blood counts, serum creatinine, thyroid-stimulating hormone, electrolyte concentrations and ECG); (iii) alcohol consumption less that 20 g per day; (iv) no evidence of hepatitis A, B, or C, of autoimmune hepatitis, or clinical signs or symptoms of inborn errors of metabolism or history of use of toxins or drugs known to induce hepatitis. The study protocol was approved by the ethics committee of the Helsinki University Central Hospital. Baseline characteristics of these subjects were included in a recent large analysis of liver fat in subjects with and without the metabolic syndrome (4).
Insulin action on glucose rate of appearance (R a , hepatic insulin sensitivity) was measured directly in 78 subjects using a prolonged low dose euglycemic hyperinsulinemic clamp to optimize conditions for measuring hepatic insulin sensitivity (14) . Characteristics of these subjects have been previously reported (15) .
Insulin action on glucose R a
Hepatic insulin sensitivity was measured using a 6-hour euglycemic hyperinsulinemic clamp. min. Glucose specific activity was determined as previously described (16) . Glucose R a was calculated using the Steele equation, assuming a pool fraction of 0.65 for glucose and a distribution volume of 200 ml/kg for glucose. Glucose R a during the last 2 hrs of the insulin infusion was used to determine the % and absolute suppressions of endogenous glucose production by insulin.
Liver fat content ( 1 H-MR spectroscopy)
Localised single voxel (2×2×2 cm 3 ) proton spectra were acquired using a 1.5-T whole-body system (Siemens Magnetom Vision, Erlangen, Germany), which consisted of a combination of whole-body and loop surface coils for radiofrequency transmitting and signal receiving. T1-weighted highresolution MRI scans were used for localisation of the voxel of interest within the right lobe of the liver. Magnetic resonance spectroscopy measurements of the liver fat were performed in the middle of the right lobe of the liver at a location that was individually determined for each subject; vascular structures and subcutaneous fat tissue were avoided when selecting the voxel. Subjects lay on their stomachs on the surface coil, which was embedded in a mattress in order to minimise abdominal movement due to breathing. The single voxel spectra were recorded using the stimulated-echo acquisition mode sequence, with an echo time of 20 ms, a repetition time of 3000 ms, a mixing time of 30 ms, 1024 data points over 1000 kHz spectral width with 32 averages. Water-suppressed spectra with 128 averages were also recorded to detect weak lipid signals. A short echo time and long repetition time was chosen to ensure a fully relaxed water signal, which was used as an internal standard. Chemical shifts were measured relative to water at 4.80 ppm. The methylene signal, which represents intracellular triglyceride, was measured at 1.4 ppm. Signal intensities were quantified by using an analysis program, VAPRO-MRUI (http://www.mrui.uab.es/mrui/). Spectroscopic intracellular triglyceride content (liver fat) was expressed as a ratio of the area under the methylene peak to that under the methylene and water peaks (X 100 = liver fat %). This measurement has been validated against histologically determined lipid content (15, 17) . When measured by proton spectroscopy, normal liver fat is approximately 5% (3). All spectra were analysed by physicists who were unaware of any of the clinical data. The reproducibility of repeated measurements of liver fat in non-diabetic subjects studied on two separate occasions by the same reader in our laboratory is 11% (4).
Measurements of body composition
Intra-abdominal and subcutaneous fat content were determined by magnetic resonance imaging (MRI) as previously described (4). The % body fat was determined using bioelectrical impedance analysis (BioElectrical Impedance Analyzer System, model number BIA-101A, RJL Systems, Detroit, MI). Waist circumference was measured midway between spina iliaca superior and the lower rib margin, and hip circumference at the level of the greater trochanters.
Analytical procedures, calculations and other measurements
Serum IGFBP-1 concentrations in the fasting state and during the last hour of insulin infusion were determined by an in-house RIA using a polyclonal antibody and human IGFBP-1 as a standard (18) . 
Statistical analyses
Non-normally distributed data were used after logarithmic transformation. The unpaired Student s t test was used to compare mean values between women and men. Analysis of covariance was used to adjust for age, gender, and BMI. Correlation analyses were performed using Pearson's rank correlation coefficient. Analysis of covariance was used to compare slopes of regression lines and intercepts between women and men. Multiple linear regression analyses were used to determine sources of variation in fS-IGFBP-1, fS-insulin, and fS-C-peptide concentrations. Data are shown as mean ± SEM or, for non-normally distributed data, as median followed by the 25%th and 75%th
percentiles. Calculations were made using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA) and SPSS 15.0 for Windows (SPSS, Chicago, IL). A p-value of less than 0.05 was considered statistically significant.
Results
Subject characteristics (Table 1) The men and women were comparable with respect to age. Women had higher BMI, waist circumference, waist-to-hip -ratio, % whole body fat, and subcutaneous fat volume than men, but intra-abdominal and liver fat were comparable between the groups. Fasting serum triglyceride, HDL and LDL cholesterol, HbA 1c , and liver enzyme concentrations were comparable between women and men, as were fS-insulin and fS-IGFBP-1 concentrations.
Circulating markers of the suppression of hepatic glucose production by insulin
The % suppression of endogenous glucose production by insulin was closely correlated with the % S-IGFBP-1 concentrations of the basal levels during the insulin infusion (p=-0.55, p<0.0001, Fig.   1 ). The % suppression of endogenous glucose production by insulin was also significantly correlated with fS-insulin (r=-0.42, p=0.0001, Fig. 2 Of circulating parameters measured in fasting serum, fS-IGFBP-1 was the best correlate of hepatic insulin sensitivity (r=0.48, p<0.0001, Fig. 2 ).
The relationships between liver fat, fS-IGFBP-1, the suppression of S-IGFBP-1 by insulin, and fS-insulin and fS-C-peptide concentrations
FS-IGFBP-1 concentrations were inversely related to liver fat content (r=-0.38, p<0.0001, Fig. 1 ).
The % S-IGFBP-1 of the basal levels during the insulin infusion was positively related to liver fat content (r=0.36, p=0.001). This relationship did not persist statistically significant after adjusting for age, gender, and BMI (r=-0.17, NS). FS-IGFBP-1 concentrations below 16 µg/l corresponded to a fatty liver (liver fat >5.6% (3)). The relationship between liver fat and other circulating markers were as follows: fS-insulin (r=0.57, p<0.0001), fS-C-peptide (p=0.57, p<0.0001), fS-triglycerides (r=0.41, p<0.0001), fS-HDL cholesterol (r=-0.37, p<0.0001), fS-ALT (r=0.58, p<0.0001), and fS-FFA (r=0.13, NS).
Hepatic insulin sensitivity and IGFBP-1: effects of age, gender, and BMI or waist
To further examine the impact of age, gender, and BMI on the relationships between hepatic insulin sensitivity and fS-IGFBP-1, fS-insulin, and fS-C-peptide, multiple linear regression analyses were employed. fS-IGFBP-1 but neither fS-insulin nor fS-C-peptide concentrations were independently associated with hepatic insulin sensitivity ( Table 2) . Of other variables, BMI was an independent correlate of hepatic insulin sensitivity in all models. The results remained essentially unchanged if BMI was replaced by waist (Table 2 ). In a model including waist, fS-insulin, fS-ALT, and fS-IGFBP-1 concentrations as independent variables, only fS-IGFBP-1 concentrations were independent determinants of hepatic insulin sensitivity ( Table 2) . Use of liver fat % instead of fS-ALT did not change the results.
Discussion
In the present study, we examined whether serum concentrations of IGFBP-1, which is produced mainly by the liver in humans (7) , are related to liver fat content and hepatic insulin sensitivity.
Liver fat and hepatic insulin sensitivity were measured using state-of-the-art -methodology in a relatively large number of non-diabetic subjects. The data show that fS-IGFBP-1 concentrations are inversely related to liver fat content, and that fS-IGFBP-1 concentrations are closely and independently related to hepatic insulin sensitivity. In addition, IGFBP-1 was a better correlate of hepatic insulin sensitivity than fS-insulin or fS-C-peptide concentrations, or any other circulating parameter measured. However, even the best model explained only 42% of the variation in hepatic insulin sensitivity.
IGFBP-1 has been shown to modify the short-term effects of IGFs (20). Insulin in turn acutely
suppresses hepatic production of serum IGFBP-1 (6, 21), which increases bioavailability of IGFs (22) . The exact function of IGFBP-1 is unknown. Tissue specific overexpression in the liver is associated with abnormalities in brain development, reduced body weight gain, reduced fecundity, and kidney damage (23) . In human studies, low circulating IGFBP-1 concentrations have been linked with increased risk of macrovascular disease in several studies but there is no evidence for a cause and effect relationship (24) . Thus, while IGFBP-1 is unique amongst known markers of hepatic insulin resistance in that it is regulated by insulin, and predicts worsening of glucose tolerance (25) , it has not yet been established to cause either abnormal glucose metabolism or cardiovascular disease.
Previous studies have suggested that fS-IGFBP-1concentrations are related to insulin sensitivity measured using HOMA-IR (8-10) or whole-body insulin sensitivity measured using the euglycemic hyperinsulinemic clamp and an insulin infusion rate of 1 mU/kg·min (11) (12) (13) . The latter reflects mainly peripheral insulin sensitivity (14) . Since glucose tracers were not used (11-13), it was not possible to distinguish between hepatic and peripheral insulin sensitivity. The associations between fS-IGFBP-1 and hepatic insulin sensitivity have not previously been studied. Use of a prolonged low-dose insulin infusion enables accurately assessment of interindividual variation in hepatic insulin sensitivity (14) . Here we show that fasting IGFBP-1 is a marker of hepatic insulin sensitivity in non-diabetic subjects independent of age, gender, BMI, and fS-insulin concentrations.
Paradoxically, serum concentrations of IGFBP-1 have been reported to be increased in patients with hepatocellular carcinoma and liver cirrhosis (26, 27) . Liver fat decreases once cirrhosis develops (28) . In addition, insulin resistance in patients with cirrhosis is peripheral rather than hepatic (29) .
The relationships between IFGBP-1 and other liver diseases have not been previously examined in humans. In the present study, we investigated how IGFBP-1 concentrations change in NAFLD, the most prevalent liver abnormality in the general population (3). Currently available markers of NAFLD, such as S-ALT and S-AST, are poor correlates of liver fat content (4). Thus, novel liverspecific markers of hepatic fat accumulation are needed. In the present study, liver fat content was quantitated using the most accurate method available to date, and related to serum IGFBP-1
concentrations. The results suggest that IGFBP-1 is inversely related to liver fat content in nondiabetic subjects.
We conclude that fS-IGFBP-1 is a novel marker of hepatic insulin sensitivity independent of age, gender, and BMI in this population of non-diabetic subjects. FS-IGFBP-1 concentrations reflected hepatic insulin sensitivity better than fS-insulin or C-peptide concentrations. In addition, we found that liver fat content is inversely related to fS-IGFBP-1. The data thus suggest that measurement of IGFBP-1 could provide a simple and reliable estimate of hepatic insulin sensitivity in humans. Data are shown as mean ± SEM or, for non-normally distributed data, as median followed by the 25%th and 75%th percentiles. 
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